16.06.2019, 2752 Zeichen

Valneva: Austrian French biotech company Valneva SE announced progress of its ongoing Phase 2 study for its leading, unique Lyme disease vaccine candidate, VLA15, into the main study phase. An independent Data Safety Monitoring Board (DSMB) has cleared two dosage levels to be used for clinical development.  Wolfgang Bender, Chief Medical Officer of Valneva, commented, “We are pleased that the run-in safety data confirm our hypothesis that we can proceed with higher doses than initially studied in Phase 1. Given the well-understood mode of action, high anti- OspA antibody titers are key to deliver a highly effective vaccine that will address the significant unmet medical need arising from the increasing spread of Lyme disease”. Preliminary Phase 2 results (primary endpoint) are anticipated – as previously announced –mid-2020.
Valneva: weekly performance: -4.03%

Zumtobel: International lighting company Zumtobel Group officially opened its new group-wide software competence centre for lighting technologies in Porto, Portugal. Tridonic, the lighting technology company of the Zumtobel Group, operates the new software competence centre. With the new technology and innovation centre, the Zumtobel Group reacts to current market trends in the areas of smart lighting, connected solutions and IoT. While the lighting industry is facing a competitive market environment, software-oriented services and solutions are gaining more importance. The Zumtobel Group invests in this fast-growing market segment in order to further refine the company’s positioning in the lighting market with innovative and smart products and solutions. “Software know-how is one of our strategic cornerstones in establishing the foundation for the future profitable growth of the company. With the new software competence centre for lighting technologies in Porto we are bundling our group-wide software know-how in order to participate in fast-growing and future-oriented market segments and fulfil our customers’ expectations and requirements of smart and connected lighting solutions”, says Alfred Felder, CEO Zumtobel Group.
Zumtobel: weekly performance: -1.01%

Sanochemia: Sanochemia Pharmazeutika AG announces that the European Patent Office positively completed the examination procedure for the patent application of Vidon^® in  Photodynamic Therapy (PDT) of bladder cancer. Vidon^® (PVP-Hypericin) is being developed as a game changing technology in the management of bladder cancer. The patent covers the treatment of bladder cancer with the PVP-Hypericin formulation developed by SANOCHEMIA. The patent will protect Vidon^® in PDT until 2035.
Sanochemia: weekly performance: 10.12%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (12/06/2019)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 102/365: Investor Gregor Rosinger mit Bonusinfo zu seinem Geburtstag heute, ich rechne ...

Bildnachweis

Aktien auf dem Radar:Flughafen Wien, DO&CO, Porr, Pierer Mobility, RHI Magnesita, Austriacard Holdings AG, CA Immo, Polytec Group, Zumtobel, Bawag, Erste Group, FACC, Kapsch TrafficCom, OMV, Palfinger, RBI, Rosenbauer, SBO, Semperit, Wienerberger, Amag, Österreichische Post, Telekom Austria, Uniqa, VIG, MTU Aero Engines, Vonovia SE, E.ON , Symrise, Fresenius Medical Care, Airbus Group.

---